SITE013-0028

SITE013 (USA) › SITE013-0028

SITE013-0028

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE013 (USA) · Dr. Clarke
consented 2025-09-27

completed

AEs

4

Serious

0

Dropout signal

–

Adverse events

4

Grade 2 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2022-09-20 (study day 169); relationship: not assessed

moderate assessed

Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2022-07-23 (study day 110); relationship: not assessed

moderate assessed

Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2022-05-27 (study day 53); relationship: NOT RELATED

moderate assessed

Grade 1 Asthenia — outcome: RECOVERED/RESOLVED; onset 2022-05-16 (study day 42); relationship: not assessed

mild assessed

Data queries

0

No data queries. Open queries would appear here for this patient.